Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi

References

• Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish catalan region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res.9, 569–581 (2009).
   PubMedGoogle Scholar
• Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals3, 2470–2494 (2010).
   Google Scholar
• Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res.8(4), 357–371 (2008).
   PubMedGoogle Scholar
• Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy8, 7–24 (2010).
   PubMedGoogle Scholar
• Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res.10(6), 707–722 (2010).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26, 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Abdulrazaq S, Al-Jazairi A, Sakra Bhareth S, Eqtefan I, Al-Suwayeh S. Brand and generic medications: are they interchangeable? Ann. Saudi Med.28, 3–41 (2008).
   Google Scholar
• Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol.1(141), 1–16 (2011).
   Google Scholar
• Godman B, Buscics A, Burkhardt T et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res.10(2), 199–207 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M, Andersson K et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomics Outcomes Res.9(1), 65–83 (2009).
   PubMedGoogle Scholar
• Gustafsson LL, Wettermark B, Godman B et al. The ‘Wise List’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol.108, 224–233 (2011).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy94, 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and aggressive generic pricing policies – an alternative approach to conserve resources? Expert Rev. Pharmacoeconomics Outcomes Res.11(1), 121–129 (2011).
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9(5), 475–484 (2009).
   PubMedGoogle Scholar
• Sakshaug S, Furu K, Karlstad O et al. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. Br. J. Clin. Pharmacol.64, 476–481 (2007).
   PubMed Web of Science ®Google Scholar
• Martikainen J, Saastamoinen L, Korhonen M et al. Impact of restricted reimbursement on the use of statins in Finland – a register-based study. Med. Care48, 761–766 (2010).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7, 137–147 (2009).
   PubMedGoogle Scholar
• Voncina L, Strizrep T, Godman B et al. Influence of prescribing restrictions compared with other demand side measures to enhance rennin–angiotensin prescribing efficiency: implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res.11(4), 469–479 (2011).
   PubMed Web of Science ®Google Scholar
• Abuelkhair M, Abdu S, Godman B, Fahmy S, Gustafsson LL. Drug utilisation study experiences from Abu Dhabi suggest multiple demand side measures will be needed to enhance prescribing efficiency; implications for the future. Pharmacoepidemiol. Drug Saf.20, S208–S209 (2011).
   Google Scholar
• Abuelkhair M, Fahmy S, Godman B, Abdu S, Gustafsson LL. Cross national comparative drug utilisation studies do provide a basis for assessing potential efficiency gains in others: experiences from Abu Dhabi. Pharmacoepidemiol. Drug Saf.20, S96 (2011).
   Google Scholar
• Wettermark B, Vlahovic-Palcevski V, Salvesen H et al. Drug utilisation research. In: Pharmacoepidemiology and Therapeutic Risk Management. Hartzema A, Tilson H, Chan K (Eds). Harvey Whitney Books Company, OH, USA (2008).
   Google Scholar
• Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur. J. Clin. Pharmacol.56, 723–727 (2000).
   PubMed Web of Science ®Google Scholar
• Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in defined daily dose in longitudinal drug consumption databases. Pharm. World Sci.32, 125–129 (2010).
   PubMedGoogle Scholar
• McGinn D, Godman B, Lonsdale J, Way R et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res.10(1), 73–85 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics27, 435–438 (2009).
   PubMed Web of Science ®Google Scholar
• Frisk P, Rydberg T, Carlsten A, Ekedahl A. Patients’ experiences with generic substitution: a Swedish pharmacy survey. JPHSR2, 9–15 (2011).
   Google Scholar
• Jack A. Balancing big pharma’s books. BMJ336, 418–419 (2008).
   PubMed Web of Science ®Google Scholar
• Awad A, Al-Saffar N. Evaluation of drug use practices at primary healthcare centers of Kuwait. Eur. J. Clin. Pharmacol.66, 1247–1255 (2010).
   PubMedGoogle Scholar
• Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations cannot obtain low prices for drugs – Lithuania as a case history to contradict this. Expert Rev. Pharmacoeconomics Outcomes Res.11(3), 341–347 (2011).
   Google Scholar
• Chua G, Hassali M, Shafie A, Awaisu A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy95, 229–235 (2010).
   PubMed Web of Science ®Google Scholar
• Kesselheim A, Misoni A, Lee J et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease – a systematic review and meta-analysis. JAMA300, 2514–2526 (2008).
   PubMed Web of Science ®Google Scholar
• Kesselheim A, Stedman M, Bubrick E et al. Seisure outcomes following the use of generic versus brand-name antiepileptic drugs. A systematic review and meta-analysis. Drugs70, 605–621 (2010).
   PubMed Web of Science ®Google Scholar
• Kanavos P. Do generics offer significant savings to the UK national health service? Curr. Med. Res. Opin.23(1), 105–116 (2007).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual. Primary Care17, 179–189 (2009).
   PubMedGoogle Scholar
• Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract.63, 1320–1326 (2009).
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract.62, 480–484 (2008).
   PubMed Web of Science ®Google Scholar
• Roland M. Linking physicians’ pay to the quality of care – a major experiment in the United Kingdom. N. Engl. J. Med.351, 1448–1454 (2004).
   PubMed Web of Science ®Google Scholar
• Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med.355, 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol.64, 1137–1138 (2008).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract.62, 76–87 (2008).
   PubMed Web of Science ®Google Scholar
• Barton S. Using clinical evidence. BMJ322, 503–504 (2001).
   PubMed Web of Science ®Google Scholar
• Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patient’s care. Lancet362, 1225–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ317, 465–468 (1998).
   PubMed Web of Science ®Google Scholar
• Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA296, 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med.167, 950–955 (2007).
   PubMed Web of Science ®Google Scholar
• Leonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol.102, 2047–2056 (2007).
   PubMed Web of Science ®Google Scholar
• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ336, 2–3 (2008).
   PubMed Web of Science ®Google Scholar
• Editorial. Failing the acid test – benefits of proton pump inhibitors may not justify the risks for many users. Arch. Intern. Med.170, 747–748 (2010).
   PubMed Web of Science ®Google Scholar
• Howell M, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med.170, 784–790 (2010).
   PubMed Web of Science ®Google Scholar